ReviewNature reviews. Clinical oncology2022
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.
Alissa J Cooper et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
333 papers cite itlatest 60 shown
this paperpooled ittrialcites it